Aaron Wagner

Andy Chen

David Faber

Kirk Winward

Taylor Cook

William Sause

Purpose. To evaluate our community-based institutional experience with plaque brachytherapy for uveal melanomas with a focus on local control rates, factors impacting disease progression, and dosimetric parameters impacting treatment toxicity. Methods and Materials. Our institution was retrospectively reviewed from 1996 to 2011; all patients who underwent plaque brachytherapy for uveal melanoma were included.  Follow-up data were collected regarding local control, distant metastases, and side effects from treatment.  Analysis was performed on factors impacting treatment outcomes and treatment toxicity. Results. A total of 107 patients underwent plaque brachytherapy, of which 88 had follow-up data available. Local control at 10 years was 94%.  Freedom from progression (FFP) and overall survival at 10 years were 83% and 79%, respectively. On univariate analysis, there were no tumor or dosimetric treatment characteristics that were found to have a prognostic impact on FFP.   Brachytherapy treatment was well tolerated, with clinically useful vision (&gt;20/200) maintained in 64% of patients.  Statistically significant dosimetric relationships were established with cataract, glaucoma, and retinopathy development (greatest P=0.05). Conclusions. Treatment with plaque brachytherapy demonstrates excellent outcomes in a community-based setting.  It is well tolerated and should remain a standard of care for COMS medium sized tumors.</jats:p

Crossref

ISRN Ophthalmology

Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience

http://downloads.hindawi.com/journals/isrn/2014/950975.pdf

Outcomes and Control Rates for I-125 Plaque Brachytherapy for Uveal Melanoma: A Community-Based Institutional Experience

Abstract

Similar works

Full text

Available Versions

Crossref